Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 5;2013(6):CD009689.
doi: 10.1002/14651858.CD009689.pub2.

Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity

Marina Demetrios  1 , Fary Khan, Lynne Turner-Stokes, Caroline Brand, Shane McSweeney
Affiliations

Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity

Marina Demetrios et al. Cochrane Database Syst Rev. .

Abstract

Background: Spasticity may affect stroke survivors by contributing to activity limitations, caregiver burden, pain and reduced quality of life (QoL). Spasticity management guidelines recommend multidisciplinary (MD) rehabilitation programmes following botulinum toxin (BoNT) treatment for post-stroke spasticity. However, the evidence base for the effectiveness of MD rehabilitation is unclear.

Objectives: To assess the effectiveness of MD rehabilitation, following BoNT and other focal intramuscular treatments such as phenol, in improving activity limitations and other outcomes in adults and children with post-stroke spasticity. To explore what settings, types and intensities of rehabilitation programmes are effective.

Search methods: We searched the Cochrane Stroke Group Trials Register (February 2012), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 12), MEDLINE (1948 to December 2011), EMBASE (1980 to January 2012), CINAHL (1982 to January 2012), AMED (1985 to January 2012), LILACS (1982 to September 2012), PEDro, REHABDATA and OpenGrey (September 2012). In an effort to identify further published, unpublished and ongoing trials we searched trials registries and reference lists, handsearched journals and contacted authors.

Selection criteria: We included randomised controlled trials (RCTs) that compared MD rehabilitation (delivered by two or more disciplines in conjunction with medical input) following BoNT and other focal intramuscular treatments for post-stroke spasticity with placebo, routinely available local services, or lower levels of intervention; or studies that compared MD rehabilitation in different settings, of different types, or at different levels of intensity. We excluded RCTs that assessed the effectiveness of unidisciplinary therapy (for example physiotherapy only) or a single modality (for example stretching, casting, electrical stimulation or splinting only). The primary outcomes were validated measures of activity level (active and passive function) according to the World Health Organization's International Classification of Functioning, Disability and Health. Secondary outcomes included measures of symptoms, impairments, participation, QoL, impact on caregivers and adverse events.

Data collection and analysis: We independently selected the trials, extracted data, and assessed methodological quality using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE). Due to the limited number of included studies, with clinical, methodological and statistical heterogeneity, quantitative meta-analysis was not possible. Therefore, GRADE provided qualitative synthesis of 'best evidence'.

Main results: We included three RCTs involving 91 participants. All three studies scored 'low quality' on the methodological quality assessment, implying high risk of bias. All studies investigated various types and intensities of outpatient rehabilitation programmes following BoNT for upper limb spasticity in adults with chronic stroke. Rehabilitation programmes included: modified constraint-induced movement therapy (mCIMT) compared with a neurodevelopmental therapy programme; task practice therapy with cyclic functional electrical stimulation (FES) compared with task practice therapy only; and occupational, manual therapy with dynamic elbow extension splinting compared with occupational therapy only. There was 'low quality' evidence for mCIMT improving upper limb motor function and spasticity in chronic stroke survivors with residual voluntary upper limb activity, up to six months, and 'very low quality' evidence for dynamic elbow splinting and occupational therapy reducing elbow range of movement at 14 weeks. Task practice therapy with cyclic FES did not improve upper limb function more than task practice therapy alone, only at 12 weeks. No studies addressed interventions in children and those with lower limb spasticity, or after other focal intramuscular treatments for spasticity.

Authors' conclusions: At best there was 'low level' evidence for the effectiveness of outpatient MD rehabilitation in improving active function and impairments following BoNT for upper limb spasticity in adults with chronic stroke. No trials explored the effect of MD rehabilitation on 'passive function' (caring for the affected limb), caregiver burden, or the individual's priority goals for treatment. The optimal types (modalities, therapy approaches, settings) and intensities of therapy for improving activity (active and passive function) in adults and children with post-stroke spasticity, in the short and longer term, are unclear. Further research is required to build evidence in this area.

PubMed Disclaimer

Conflict of interest statement

The authors are therapists or clinicians in the field of Physical and Medical Rehabilitation with a clinical interest in management of spasticity.

Lynne Turner‐Stokes has received honoraria from Ipsen Ltd and from Allergan on a number of occasions over the last few years for lecturing and running training courses and workshops – particularly with respect to the use of goal attainment scaling in spasticity. She has been involved with the development of clinical guidelines and consensus statements regarding spasticity management that were sponsored variously by Ipsen Ltd and Allergan. She has received consultancy fees for advising on research projects and for data analysis, and has held research grants from Ipsen Ltd to conduct studies relating to spasticity management. She has also published papers and presented abstracts at conferences reporting trials and other studies relating to the use of botulinum toxin for spasticity. Some of her work in this area may have been eligible for inclusion in the review.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD009689

References

References to studies included in this review

Lai 2009 {published and unpublished data}
    1. Lai J, Francisco G, Willis FB. Dynamic splinting after treatment with botulinum toxin type A: a randomized controlled pilot study. Advances in Therapy 2009;26(2):241‐8. - PubMed
Sun 2010 {published and unpublished data}
    1. Sun S, Hsu C, Sun H, Hwang C, Yang C, Wang J. Combined botulinum toxin type A with modified constraint induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabilitation and Neural Repair 2010;24(1):34‐41. - PubMed
Weber 2010 {published and unpublished data}
    1. Weber D, Skidmore E, Niyonkuru C, Chang C, Huber L, Munin M. Cyclic functional electrical stimulation does not enhance gains in hand grasp function when used as an adjunct to Onabotulinumtoxin A and task practice therapy: a single‐blind, randomized controlled pilot study. Archives of Physical Medicine and Rehabilitation 2010;91:679‐86. - PMC - PubMed

References to studies excluded from this review

Baricich 2008 {published data only}
    1. Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single‐blinded, randomized pilot study of botulinum toxin type A combined with non‐pharmacological treatment for spastic foot. Journal of Rehabilitation Medicine 2008;40(10):870‐2. - PubMed
Bayram 2006 {published data only}
    1. Bayram S, Sivrioglu K, Karli N, Ozcan O. Low‐dose botulinum toxin with short‐term electrical stimulation in post‐stroke spastic drop foot: a preliminary study. American Journal of Physical Medicine and Rehabilitation 2006;85(1):75‐81. - PubMed
Borg 2011 {published data only}
    1. Borg J, Ward A, Wissel J, Kulkarni J, Sakel M, Ertzgaard P, et al. Rationale and design of a multicentre, double‐blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post‐stroke focal spasticity. Journal of Rehabilitation Medicine 2011;11(43):15‐22. - PubMed
Carda 2011 {published data only}
    1. Carda S, Invernizzi M, Baricich A, Cisari C. Casting, taping or stretching after botulinum toxin type A for spastic equinus foot: a single‐blind randomized trial on adult stroke patients. Clinical Rehabilitation 2011;25(12):1119‐27. - PubMed
Childers 2004 {published data only}
    1. Childers M, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, et al. Dose‐dependent response to intramuscular botulinum toxin type A for upper‐limb spasticity in patients after a stroke. Archives of Physical Medicine and Rehabilitation 2004;85(7):1063‐9. - PubMed
Clark 2011 {published data only}
    1. Clark PC, Aycock DM, Reiss A, Tanner D, Wolf SL. Treatment for stroke survivor upper extremity spasticity may benefit caregivers: a preliminary study. Stroke 2011;42(3):e61.
Clarke 2003 {published data only}
    1. Clarke CE. A pragmatic randomised controlled trial of botulinum toxin and functional electrical stimulation in equinovarus spasticity. Current Controlled Trials (http://www.controlled‐trials.com/) [ISRCTN 95945958] 2003.
Cui 2006 {published data only}
    1. Cui LH. Domesitical botulinum toxin type A injection in the treatment of post‐stroke patients with upper extremity spasticity. Chinese Journal of Neurology 2006;39(7):463‐6.
Duarte 2011 {published data only}
    1. Duarte E, Marco E, Cervantes C, Diaz D, Chiarella SC, Escalada F. Effects of botulinum toxin type A and electrostimulation on distal flexor spasticity of the upper limb in stroke. Randomized clinical trial. Rehabilitacion (Madrid) 2011;45(3):194‐201.
Farina 2008 {published data only}
    1. Farina S, Migliorini C, Gandolfi M, Bertolasi L, Casarotto M, Manganotti P, et al. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Functional Neurology 2008;23(2):87‐91. - PubMed
Guo 2006 {published data only}
    1. Guo F. Botulinum toxin type A plus rehabilitative training for improving the motor function of the upper limbs and activities of daily life in patients with stroke and brain injury. Neural Regeneration Research 2006;1(9):859‐61.
Hesse 1995 {published data only}
    1. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short‐term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neuroscience Letters 1995;201(1):37‐40. - PubMed
Hesse 1998 {published data only}
    1. Hesse S, Reiter F, Konrad M, Jahnke MTl. Botulinum toxin type A and short‐term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double‐blind, placebo‐controlled trial. Clinical Rehabilitation 1998;12(5):381‐8. - PubMed
Johnson 2004 {published data only}
    1. Johnson CA, Burridge JH, Strike PW, Wood DE, Swain ID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Archives of Physical Medicine and Rehabilitation 2004;85(6):902‐9. - PubMed
Karadag‐Saygi 2010 {published data only}
    1. Karadag‐Saygi E, Cubukcu‐Aydoseli K, Kablan N, Ofluoglu D. The role of kinesiotaping combined with botulinum toxin to reduce plantar flexors spasticity after stroke. Topics in Stroke Rehabilitation 2010;17(4):318‐22. - PubMed
Kent 2006 {published data only}
    1. Kent RM, Robertson AJ, Tennant A. Optimising botulinum toxin (BTX‐A) treatment of upper limb spasticity in stroke using orthotics and physiotherapy: a randomized controlled trial. Neurorehabilitation and Neural Repair 2006;20(1):196.
Lagalla 1997 {published data only}
    1. Lagalla G, Danni M, Reiter F, Cerevalo MG, Fiorani C, Severini S, et al. Enhancement of botox efficiency for upper limb spasticity using forearm splints. Journal of Neurologic Rehabilitation 1997; Vol. 11:138.
Marco 2007 {published data only}
    1. Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double‐blind randomized clinical trial. Journal of Rehabilitation Medicine 2007;39(6):440‐7. - PubMed
Mawson 2007 {published data only}
    1. Mawson S, Datta D, Clarke A, Harris I. Investigating the effects of botulinum toxin injections and physiotherapy on upper limb function for stroke patients: a randomised controlled trial. Physiotherapy 2007;93 Suppl 1:S564.
McCrory 2009 {published data only}
    1. McCrory P, Turner‐Stokes L, Baguley I, Graaff S, Katrak P, Sandanam J, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi‐centre randomized placebo controlled study of the effects on quality of life and other person‐centred outcomes. Journal of Rehabilitation Medicine 2009;41:536‐44. - PubMed
Meythaler 2009 {published data only}
    1. Meythaler JM, Vogtle L, Brunner RC. A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke. Archives of Physical Medicine and Rehabilitation 2009;90(9):1453‐61. - PubMed
Pieber 2011 {published data only}
    1. Pieber K, Herceg M, Wick F, Grim‐Stieger M, Bernert G, Paternostro‐Sluga T. Functional electrical stimulation combined with botulinum toxin type A to improve hand function in children with spastic hemiparesis ‐ a pilot study. Wiener Klinische Wochenschrift 2011;123(3‐4):100‐5. - PubMed
Pisano 2002 {published data only}
    1. Pisano F, Miscio G, Delconte C, Pianca D, Colombo R. Effects of short‐term electrical stimulation in addition to botulinum toxin A treatment in the upper limb spasticity. Proceedings of the 3rd World Congress in Neurological Rehabilitation. Italy, Venice. 2‐6 April 2002 (Abst T52).
Reiter 1998 {published data only}
    1. Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low‐dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Archives of Physical Medicine and Rehabilitation 1998;79(5):532‐5. - PubMed
Shaw 2011 {published data only}
    1. Shaw, LC, Price CI, Wijck FM, Shackley P, Steen N, Barnes MP, et al. Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke 2011;42(5):1371‐9. - PubMed
Sheikh 2006 {published data only}
    1. Sheikh M, Olyaee GR, Abolfazli R, Hosseini HA. Assessment of the effects of neurodevelopmental treatment (NDT) and botulinum toxin injection on spastic hemiplegic patients. Journal of Iran University of Medical Sciences 2006;13(51):156.
Sisto 2001 {published data only}
    1. Sisto SA, Bond Q, Chen B, Shiflett S, Elovic E, Johnston MV. Efficacy of acupressure versus botox in the treatment of spastic gait in stroke survivors. Journal of Stroke and Cerebrovascular Diseases 2001;10(4):198.
van Wijck 2006 {published and unpublished data}
    1. Wijck FMJ, Mackenzie J, Pandyan AD, Barnes MP, Johnson GR. Improving functional activity of the spastic upper limb in the chronic stage after stroke following botulinum toxin. Neurorehabilitation and Neural Repair 2006; Vol. 20, issue 1:173.
Werner 2011 {published data only}
    1. Werner C, Mach H, Melzer I, Hesse S. Highly paretic patients within four to six weeks after stroke: an early botulinum toxin A treatment may prevent a disabling finger flexor spasticity six months later. Annals of Physical and Rehabilitation Medicine Conference 2011; Vol. 54 Suppl 1:e137.
Wolf 2007 {published data only}
    1. Wolf S. Evaluation of BOTOX® with rehabilitation therapy for the treatment of wrist and hand spasticity in post‐stroke patients (botox/rehab). Annals of Physical and Rehabilitation Medicine Conference 2011:e137.

References to ongoing studies

Graham 2009 {published data only}
    1. NCT00945295. Efficacy and safety study of botulinum neurotoxin A with rehabilitation versus botulinum neurotoxin A alone in treatment of post‐stroke spasticity. ClinicalTrials.gov/show/NCT00945295 (accessed 18 January 2012).
Lannin 2011 {published data only}
    1. Lannin N, Crotty M, Radcliffe J. The effectiveness of best practise therapy after Botulinum Toxin A injections for adults diagnosed with neurological impairment and onset of spasticity. Australian New Zealand Clinical Trials Registry (ANZCTR) (http://www.anzctr.org.au) ACTRN12612000091808 (accessed 12 February 2012).

Additional references

Ada 2006
    1. Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disability and Rehabilitation 2006;28(13‐14):891‐7. - PubMed
Bakheit 2011
    1. Bakheit AM, Fheodoroff K, Molteni F. Spasticity or reversible muscle hypertonia?. Journal of Rehabilitation Medicine 2011;43(6):556‐7. - PubMed
Barnes 2001
    1. Barnes MP. Upper Motor Neurone Syndrome and Spasticity. Cambridge: Cambridge University Press, 2001.
Bhakta 1996
    1. Bhakta B, Cozens J, Bamford J, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61:30–5. - PMC - PubMed
Bhakta 2000
    1. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. Journal of Neurology, Neurosurgery, and Psychiatry 2000;69:217‐21. - PMC - PubMed
Bohannon 1987
    1. Bohannon RW, Smith MB. Inter‐rater reliability of a modified Ashworth scale of muscle spasticity. Physical Therapy 1987;67:206‐7. - PubMed
Brashear 2002
    1. Brashear A, Gordon M, Elovic E, Kassicieh D, Marciniak C, Lee C, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. New England Journal of Medicine 2002;347(6):395–400. - PubMed
De Jong 2004
    1. DeJong G, Horn S, Gassaway J, Slavin M, Dijkers M. Toward a taxonomy of rehabilitation interventions: using an inductive approach to examine the 'Black Box' of rehabilitation. Archives of Physical Medicine and Rehabilitation 2004;85:678‐86. - PubMed
De Paiva 1999
    1. Paiva A, Meuniere FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences of the United States of America 1999;96:3200‐5. - PMC - PubMed
Elia 2009
    1. Elia A, Filippini G, Calandrella D, Albanese A. Botulinum neurotoxins for post‐stroke spasticity in adults: a systematic review. Movement Disorders 2009;24(6):801‐12. - PubMed
Esquenazi 2001
    1. Esquenazi A, Mayer N. Botulinum toxin for the management of muscle overactivity and spasticity after stroke. Current Atherosclerosis Reports 2001;3:295–8. - PubMed
Esquenazi 2010
    1. Esquenazi A, Novak I, Sheean G, Singer B, Ward A. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments – introduction. European Journal of Neurology 2010;17 Suppl 2:1‐8. - PubMed
Esquenazi 2011
    1. Esquenazi A. The human and economic burden of poststroke spasticity and muscle overactivity. Journal of Clinical Outcomes Management 2011;18(1):607‐14.
Francis 2004
    1. Francis HP, Wade DT, Turner‐Stokes L, Kingswell RS, Dott CS, Coxon EA. Does reducing spasticity translate into functional benefit? An exploratory meta‐analysis. Journal of Neurology, Neurosurgery, and Psychiatry 2004;75:1547–51. - PMC - PubMed
Gassaway 2005
    1. Gassaway J, Horn SD, DeJong G, Smout RJ, Clark C, James R. Applying the clinical practice improvement approach to stroke rehabilitation: methods used and baseline results. Archives of Physical Medicine and Rehabilitation 2005;86 Suppl 2:S16‐33. - PubMed
Gowland 1993
    1. Gowland C, Stratford P, Ward M, Moreland J, Torresin W, Hullenaar S, et al. Measuring physical impairment and disability with the Chedoke‐McMaster Stroke Assessment. Stroke 1993;24:58‐63. - PubMed
Gracies 2001
    1. Gracies JM. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Physical Medicine and Rehabilitation Clinics of North America 2001;12:747‐68. - PubMed
Green 2002
    1. Green J, Forster A. Reliability of gait speed measured by a timed walking test in patients one year after stroke. Clinical Rehabilitation 2002;16:306‐14. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Khan 2007
    1. Khan F, Turner‐Stokes L, Ng L, Kilpatrick T, Amatya B. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006036.pub2] - DOI - PMC - PubMed
Kiresuk 1968
    1. Kiresuk T, Sherman R. Goal attainment scaling: a general method of evaluating comprehensive mental health programmes. Community Mental Health Journal 1968;4:443‐53. - PubMed
Lance 1980
    1. Lance JW. Spasticity: disordered motor control. In: Feldman RG, Young RR, Koella WP editor(s). Symposium Synopsis. Chicago: Year Book Medical Publishers, 1980:485‐94.
Langhorne 2011
    1. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011;377(9778):1693‐702. - PubMed
Levy 2007
    1. Levy CE, Giuffrida C, Richards L, Wu S, Davis S, Nadeau SE. Botulinum Toxin A, evidence‐based exercise therapy, and constraint‐induced movement therapy for upper‐limb hemiparesis attributable to stroke a preliminary study. American Journal of Physical Medicine and Rehabilitation 2007;86:696–706. - PubMed
Lundstrom 2010
    1. Lundstrom E, Smits A, Borg J, Terent A. Four‐fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010;41(2):319–24. - PubMed
Lyle 1981
    1. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. International Journal of Rehabilitation Research 1981;4:483‐92. - PubMed
Lyons 2008
    1. Lyons BE, Moore P, Bhakta BB, Bamford JM, Cardwell C, Logan ID. Botulinum toxin for adult spasticity after stroke or non‐progressive brain lesion. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD002926.pub2] - DOI
Mackay 2004
    1. Mackay J, Mensah G, World Health Organization (WHO). The atlas of heart disease and stroke. http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke... 2004:50.
Malhotra 2009
    1. Malhotra S, Pandyan AD, Day CR, Jones PW, Hermens H. Spasticity, an impairment that is poorly defined and poorly measured. Clinical Rehabilitation 2009;23:651‐8. - PubMed
Mehrholz 2005
    1. Mehrholz J, Wagner K, Meissner D, Grundmann K, Zange C, Koch R, et al. Reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in adult patients with severe brain injury: a comparison study. Clinical Rehabilitation 2005;19(7):751–9. - PubMed
Monaghan 2011
    1. Monaghan K, Horgan F, Blake C, Cornall C, Hickey PPM, Lyons BE, et al. Physical treatment interventions for managing spasticity after stroke. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD009188] - DOI
Murphy 2000
    1. Murphy B, Herman H, Hawthorne G, Pinzone T, Evert H. Australian WHOQoL instruments: user's manual and interpretation guide. Australian WHOQoL Field Study Centre, Melbourne, Australia 2000.
Olver 2010
    1. Olver J, Esquenazi A, Fung V, Singer B, Ward A. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. European Journal of Neurology 2010;17 Suppl 2:57‐73. - PubMed
Pandyan 2005
    1. Pandyan AD, Gregoric M, Barnes MP, Wood D, Wijck F, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability and Rehabilitation 2005;27(1/2):2‐6. - PubMed
Peurala 2011
    1. Peurala SH, Kantanen MP, Sjogren T, Paltamaa J, Maarit Karhula M, Heinonen A. Effectiveness of constraint‐induced movement therapy on activity and participation after stroke: a systematic review and meta‐analysis of randomized controlled trials. Clinical Rehabilitation 2011;26(3):209‐23. - PubMed
Podsiadlo 1991
    1. Podsiadlo D, Richardson S. The timed up and go: a test of basic functional mobility for frail elderly persons. Journal of the American Geriatrics Society 1991;39:142‐8. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Robinson 1983
    1. Robinson BC. Validation of a Caregiver Strain Index (CSI). Journal of Gerontology 1983;38(3):344‐8. - PubMed
Rousseaux 2002
    1. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. Journal of Neurology 2002;249(1):76‐84. - PubMed
Sheean 1998
    1. Sheean G. Pathophysiology of spasticity. In: Sheean G editor(s). Spasticity Rehabilitation. 1st Edition. London: Churchill Communications Europe Ltd, 1998:17‐38.
Sheean 2001
    1. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?. Current Opinion in Neurology 2001;14:771‐6. - PubMed
Sheean 2010
    1. Sheean G, Lannin N, Turner‐Stokes L, Rawicki B, Snow B. Botulinum toxin assessment, intervention and after‐care for upper limb hypertonicity in adults: international consensus statement. European Journal of Neurology 2010;17 Suppl 2:74‐93. - PubMed
Slawek 2005
    1. Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: an open‐label study with individualised, flexible injection regimens. Neurological Sciences 2005;26:32‐9. - PubMed
Stevenson 2010
    1. Stevenson VL. Rehabilitation in practice: spasticity management. Clinical Rehabilitation 2010;24(4):293‐304. - PubMed
Stiens 2002
    1. Stiens S, O'Young B, Young M. Person‐centred rehabilitation: interdisciplinary intervention to enhance patient enablement. In: O'Young B, Young M, Stiens S editor(s). Physical Medicine and Rehabilitation Secrets. 2nd Edition. USA: Hanley & Belfus, 2002:4‐9.
Tennant 2007
    1. Tennant A. Goal attainment scaling: current methodological challenges. Disability and Rehabilitation 2007;29(20–21):1583‐8. - PubMed
Turner‐Stokes 2005
    1. Turner‐Stokes L, Disler P, Nair A, Wade DT. Multidisciplinary rehabilitation for acquired brain injury in adults of working age. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004170.pub2] - DOI - PubMed
Turner‐Stokes 2009
    1. Turner‐Stokes L, Ward AB. Spasticity in Adults: Management using Botulinum Toxin. National Guidelines. London: Royal College of Physicians, 2009.
Turner‐Stokes 2010a
    1. Turner‐Stokes L, Ashford S, Williams H. Poster 435: A UK pilot for a large international prospective cohort analysis of the use of Botulinum Toxin A (BoNT‐A) in upper limb spasticity (abstract). Physical Medicine and Rehabilitation 2010;2 Suppl 9:S190–1.
Turner‐Stokes 2010b
    1. Turner‐Stokes L, Ashford S, Nair A. Poster 19: Psychometric evaluation of the Arm Activity Measure (ArmA) – a measure of active and passive function in the hemiparetic arm. Physical Medicine and Rehabilitation 2010;2 Suppl 9:S13–4.
Turner‐Stokes 2010c
    1. Turner‐Stokes L, Baguley I, Graaff S, Katrak P, Davies L, McCrory P, et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double‐blind placebo‐controlled randomized clinical trial. Journal of Rehabilitation Medicine 2010;42:81‐9. - PubMed
Van der Lee 2004
    1. Lee JH, Beckerman H, Knoll DL, Vet HC, Bouter LM. Clinimetric properties of the motor activity log for the assessment of arm use in hemiparetic patients. Stroke 2004;35:1410‐4. - PubMed
Wade 2010
    1. Wade DT, Bovend’Eerdt TJ. How to set SMART goals. Clinical Rehabilitation 2010;24(4):382.
Watkins 2002
    1. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clinical Rehabilitation 2002;16:515‐22. - PubMed
WHO 1989
    1. World Health Organization. Recommendations on stroke prevention, diagnosis, and therapy. Stroke 1989;20:1407‐31. - PubMed
WHO 2001
    1. World Health Organization (WHO). International Classification of Functioning Disability and Health (ICF). WHO Geneva 2001.
WHO 2003
    1. WHO. The World Health Report 2003: Shaping the Future. http://www.who.int/whr/2003/en/whr03_en.pdf (accessed 2 September 2011) October 2003.
Wolf 2006
    1. Wolf SL, Winstein CJ, Miller JP, Taub E, Uswatte G, Morris D, et al. Effect of constraint‐induced movement therapy on upper extremity function 3 to 9 months after stroke. The EXCITE randomized clinical trial. JAMA 2006;296(17):2095‐104. - PubMed

Publication types

LinkOut - more resources